Ewing sarcoma represents a clinically devastating, small round blue cell malignancy defined by apathognomonic chromosomal translocation, most frequently yielding the oncogenic fusiontranscription factor EWS-FLI1. This aberrant master regulator belongs to the broader landscape ofFET-family driven malignancies, where the intrinsically disordered N-terminal prion-like domainderived from EWSR1 or FUS functions as a potent transactivation engine. Under physiologicalconditions, the FET family proteins (FUS, EWSR1, TAF15) orchestrate critical steps in cellularhomeostasis, including nascent pre-mRNA transcription, splicing coordination, andnucleocytoplasmic RNA shuttling via interactions with RNA polymerase II. However, in the contextof the EWS-FLI1 fusion, the EWSR1 domain undergoes heavy phase separation on polymorphicmicrosatellite blocks, hijacking cellular chromatin remodeling machinery to directly reprogram thecore transcriptome. Crucially, while EWS-FLI1 acts as a pervasive transcriptional repressor ofdifferentiation genes, it simultaneously induces the hyper-activation of pro-survival loci, embeddingspecific biochemical and structural motifs within emerging transcripts. Emerging evidence indicatesthat the aggressive phenotype of Ewing sarcoma relies not only on this raw transcriptional overdrivebut also on a highly coordinated post-transcriptional interactome, where the structurally conservedRNA-binding protein motifs within tumor-specific promoters and 5'UTRs act as an obligatory nexusfor downstream translational survival. Consequently, targeting Ewing sarcoma requires shifting fromblunt systemic inhibition to the rational design of synthetic genetic circuits capable of sensing theseconvergent, FET-family restricted molecular blueprints at a single-nucleotide resolution.
Trybuła Marcel (2026) studied this question.